Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
about
sameAs
Mitoxantrone for multiple sclerosisSystematic review of clinical practice guidelines related to multiple sclerosisRole of immunosuppressive therapy for the treatment of multiple sclerosisTherapeutic decisions in multiple sclerosis: moving beyond efficacyCurrent and emerging therapies in multiple sclerosis: a systematic reviewTherapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Infection risk in patients on multiple sclerosis therapeutics.The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.Cardiovascular Dysfunction in Multiple Sclerosis.PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple sclerosis M.smegmatis modelSex-dependent treatment of chronic EAE with partial MHC class II constructs.Drug therapy for multiple sclerosis.Targeting NOX enzymes in the central nervous system: therapeutic opportunities.Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Chemotherapeutics in the treatment of multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.Painful and involuntary multiple sclerosis.Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) studyLights and shadows of cyclophosphamide in the treatment of multiple sclerosisAsymmetric enzymatic glycosylation of mitoxantronePredictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning.Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in GermanyAcute myeloid leukemia developing in patients with autoimmune diseases.Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationA prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyGuidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations.Fingolimod for the treatment of relapsing multiple sclerosis.Current disease-modifying treatment of multiple sclerosis.Managing MS in a changing treatment landscape.Treatment of multiple sclerosis: current concepts and future perspectives.Treating multiple sclerosis with natalizumab.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
P2860
Q24202866-9C125F32-F142-4D2E-86D8-4DEE705145EFQ26824425-3FB6B40A-7A37-4887-A6A6-197ECA4D842EQ26827467-31087B2A-23DD-41A8-96E1-42A1BBEA0A3DQ28541039-908712F5-959C-4ACB-AC7A-F2CB5A6F4DEAQ29010983-E535550E-AF9E-4581-B049-1A5AFA7C02E6Q30354658-80CE5B94-B078-4C3E-B99C-AC64433FB8D2Q30458930-B640E423-2EA0-4CBC-9DFE-C5711D97FCCDQ30908652-59B72531-893A-4EC6-8F1C-00BAF88787BCQ30986945-033EFC8A-A6F7-46A0-9674-F46F90625245Q33572376-52762704-C413-4259-BFC7-BF56CB290077Q33591700-9A443F7D-001E-464F-B68F-555526670C64Q33645392-F6C1F799-DBB2-40D7-AA42-5403186C664DQ33990246-58FFD30D-1F11-409B-90EE-CE069E08235EQ34285497-45D28220-A8B9-43CA-AB9F-47AD9352E69DQ34314312-C83B4C66-A633-4B99-A845-20ECC090C788Q34409536-6D673542-E7A3-4003-BE91-E6B8256753F7Q34468304-CE271115-7893-4790-898A-D06B5D99D563Q34478828-03222C24-E049-42EA-86C1-231CA750D885Q34729032-8BA4AE38-4ED1-416B-A8B5-AE1E76735DACQ34786264-93A732C2-431A-4173-90C5-8C527EB0D3D4Q34810005-811F9B12-4853-453F-A361-6D5CE119365DQ34922742-006F8A15-753D-48E5-B3DB-8AADB185260BQ34996995-CA2A4BCE-A25C-4878-A093-FB2AAE806320Q35137514-25296691-64B3-4FEC-9E85-FFB706F67079Q35738898-C54CDB14-1F87-491E-BBD5-F687432956EBQ35825923-EEE6B1E9-DAEA-4C27-843A-0E0B836D1EFDQ36006358-D77E00DB-005D-4523-ADCB-8E67D6D42869Q36020897-74291995-0386-405A-8FE5-BA6F0A640244Q36075481-23C5C4BE-BFF1-4C59-B4DD-023BED289C36Q36731484-838A849A-A834-47D1-B9F3-BF0483EA2993Q36901406-26113198-26C5-4EAA-86EA-0916FD99F793Q36975701-CEC0F822-8C11-4AC3-8B3C-42C7AE08D574Q36982030-B34B9ADB-2E7E-43C1-8B43-F070E58EE3CAQ37392585-51C980BF-3907-40CC-BA91-3CD6AA65E7A8Q37821010-70A7101C-2D0E-4402-BE84-53E5C6916AB7Q37855719-52D828F5-3125-40FA-BEBF-1E0210118D14Q37857752-EF835532-45F0-454F-AB7E-3C8F33A61480Q37884434-C8A04F2A-9C72-4267-AF76-96FFBB05D5B4Q37957123-57B30B76-B31D-416D-9050-951990C66379Q38051577-1546A26A-8FD5-4FA9-B7C3-BE8CB90AAA5D
P2860
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evidence Report: The efficacy ...... American Academy of Neurology
@ast
Evidence Report: The efficacy ...... American Academy of Neurology
@en
Evidence Report: The efficacy ...... American Academy of Neurology
@en-gb
Evidence Report: The efficacy ...... American Academy of Neurology
@nl
type
label
Evidence Report: The efficacy ...... American Academy of Neurology
@ast
Evidence Report: The efficacy ...... American Academy of Neurology
@en
Evidence Report: The efficacy ...... American Academy of Neurology
@en-gb
Evidence Report: The efficacy ...... American Academy of Neurology
@nl
prefLabel
Evidence Report: The efficacy ...... American Academy of Neurology
@ast
Evidence Report: The efficacy ...... American Academy of Neurology
@en
Evidence Report: The efficacy ...... American Academy of Neurology
@en-gb
Evidence Report: The efficacy ...... American Academy of Neurology
@nl
P2093
P2860
P3181
P1433
P1476
Evidence Report: The efficacy ...... American Academy of Neurology
@en
P2093
Gary Gronseth
James J Marriott
Paul W O'Connor
Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
P2860
P304
P3181
P356
10.1212/WNL.0B013E3181DC1AE0
P407
P577
2010-05-01T00:00:00Z